ReviewWorld journal of gastroenterology2015
Reversibility and heritability of liver fibrosis: Implications for research and therapy.
Review in World journal of gastroenterology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 1 synthesis or guideline pooled it, 68 citations in OpenAlex.
- The efficacy of resveratrol in the treatment of liver fibrosis: a systematic review and meta-analysis of preclinical studies.Frontiers in nutrition · 2025Pooled it
- Decoding fibroblast activation: Transcriptional networks in hepatic stellate cells and across fibrotic organs (Review).International journal of molecular medicine · 2026Review
- Assessment of MRI susceptibility-weighted imaging-based liver-to-muscle signal intensity ratios for the staging of liver fibrosis.Insights into imaging · 2026Article
- Methylome differences among barley inbreds and their association with genomic, transcriptomic, and phenotypic variation.Journal of experimental botany · 2026Article
- The role of the interleukin family in liver fibrosis.Frontiers in immunology · 2025Review
- A Murine Model of Non-Wear-Particle-Induced Aseptic Loosening.Biomimetics (Basel, Switzerland) · 2024Article
- Exploring Fibrosis Pathophysiology in Lean and Obese Metabolic-Associated Fatty Liver Disease: An In-Depth Comparison.International journal of molecular sciences · 2024Review
- Identification of functional genes in liver fibrosis based on bioinformatics analysis of a lncRNA-mediated ceRNA network.BMC medical genomics · 2024Article
- The role of PI3k/AKT signaling pathway in attenuating liver fibrosis: a comprehensive review.Frontiers in medicine · 2024Review
- Progress on traditional Chinese medicine in improving hepatic fibrosis through inhibiting oxidative stress.World journal of hepatology · 2023Review
- Correlation between SDF-1α, CD34 positive hematopoietic stem cells and CXCR4 expression with liver fibrosis in CCl4 rat model.BMC gastroenterology · 2023Article
- Article
- Salvianolic acid B inhibits the progression of liver fibrosis in rats via modulation of the Hedgehog signaling pathway.Experimental and therapeutic medicine · 2022Article
- Kinsenoside Protects Against Radiation-Induced Liver FibrosisFrontiers in pharmacology · 2022Article
- Transcriptome analysis reveals the molecular mechanism of Yiqi Rougan decoction in reducing CClChinese medicine · 2021Article
- Review
- Role of long non‑coding RNAs and related epigenetic mechanisms in liver fibrosis (Review).International journal of molecular medicine · 2021Review
- RNF2 Mediates Hepatic Stellate Cells Activation by Regulating ERK/p38 Signaling Pathway in LX-2 Cells.Frontiers in cell and developmental biology · 2021Article
- MiR-34c promotes hepatic stellate cell activation and Liver Fibrogenesis by suppressing ACSL1 expression.International journal of medical sciences · 2021Article
- Diffusion tensor imaging quantifying the severity of chronic hepatitis in rats.BMC medical imaging · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liver fibrosis continues to be a major health problem worldwide due to lack of effective therapy. If the etiology cannot be eliminated, liver fibrosis progresses to cirrhosis and eventually to liver failure or malignancy; both are associated with a fatal outcome. Liver transplantation, the only curative therapy, is still mostly unavailable. Liver fibrosis was shown to be a reversible process; however, complete reversibility remains debatable. Recently, the molecular markers of liver fibrosis were shown to be transmitted across generations. Epigenetic mechanisms including DNA methylation, histone posttranslational modifications and noncoding RNA have emerged as major determinants of gene expression during liver fibrogenesis and carcinogenesis. Furthermore, epigenetic mechanisms have been shown to be transmitted through mitosis and meiosis to daughter cells and subsequent generations. However, the exact epigenetic regulation of complete liver fibrosis resolution and inheritance has not been fully elucidated. This communication will highlight the recent advances in the search for delineating the mechanisms governing resolution of liver fibrosis and the potential for multigenerational and transgenerational transmission of fibrosis markers. The fact that epigenetic changes, unlike genetic mutations, are reversible and can be modulated pharmacologically underscores the unique opportunity to develop effective therapy to completely reverse liver fibrosis, to prevent the development of malignancy and to regulate heritability of fibrosis phenotype.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.